Skip to main content
. 2022 Sep 28;12:850363. doi: 10.3389/fonc.2022.850363

Figure 4.

Figure 4

Serum-derived piR-hsa-164586 of extracellular vesicles is a potential biomarker for NSCLC patients. (A) qRT-PCR analysis the expression level of piR-hsa-164586 of extracellular vesicles in patients with stage of NSCLC (n = 95), all stage of NSCLC (n = 115) and healthy persons (n = 47). (*p < 0.05,**p < 0.01); (B, C) ROC curve analysis for piR-hsa-164586 of extracellular vesicles in distinguishing stageor all stage of NSCLC from healthy individuals.